KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses: 2009-2025

Historic Operating Expenses for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $41.0 million.

  • Rigel Pharmaceuticals' Operating Expenses fell 0.51% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 10.24%. This contributed to the annual value of $155.1 million for FY2024, which is 12.89% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Operating Expenses stood at $41.0 million for Q3 2025, which was up 1.13% from $40.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Operating Expenses high stood at $49.2 million for Q4 2022, and its period low was $32.2 million during Q2 2023.
  • Its 3-year average for Operating Expenses is $37.7 million, with a median of $38.8 million in 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Operating Expenses increased by 28.47% in 2021 and then slumped by 31.25% in 2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Operating Expenses (Quarterly) stood at $41.8 million in 2021, then rose by 17.62% to $49.2 million in 2022, then tumbled by 31.25% to $33.8 million in 2023, then grew by 21.03% to $40.9 million in 2024, then fell by 0.51% to $41.0 million in 2025.
  • Its last three reported values are $41.0 million in Q3 2025, $40.6 million for Q2 2025, and $40.6 million during Q1 2025.